Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label phase 2 dose-finding study of pacritinib in myelofibrosis previously treated with ruxolitinib
MOH_2018-11-07_003672Phase 2Not yet recruiting
- Sponsor
- CTI BioPharma Corp.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pacritinib in myelofibrosis (MF), primary myelofibrosis (PMF) and post-polycythemia vera myelofibrosis (PPV-MF) (3 arms), sponsored by CTI BioPharma Corp. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on MOH_2018-11-07_003672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-07_003672.